Brief Reports
Copyright ©The Author(s) 2005.
World J Gastroenterol. Aug 21, 2005; 11(31): 4895-4898
Published online Aug 21, 2005. doi: 10.3748/wjg.v11.i31.4895
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Tumor size in BALB/c mice implanted with CT26 colorectal adenocarcinoma cells. (●) control group, saline only; (○) etoposide group, 5 mg/kg×2; (▼) RT group, 5 Gy×2; (▽) combination therapy group (etoposide plus RT).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Changes in body weight of BALB/c mice implanted with CT26 colorectal adenocarcinoma cells. (●) control group, saline only; (○) etoposide group, 5 mg/kg×2; (▼) RT group, 5 Gy×2; (△) combination therapy group (etoposide plus RT).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Plasma ALT and creatinine levels after killing of BALB/c mice implanted with CT26 colorectal adenocarcinoma cells. From left to right are: control group, etoposide group, RT group, and combination therapy group.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Serial changes in leukocyte counts of BALB/c mice implanted with CT26 colorectal adenocarcinoma cells. (●) control group, saline only; (○) etoposide group, 5 mg/kg×2; (▼) RT group, 5 Gy×2; (△) combination therapy group (etoposide plus RT).